Biotech: Page 2

  • Brain MRI scan
    Image attribution tooltip
    iStock via Getty Images

    Beer, dolphins and more discoveries that could shed light on Alzheimer’s disease

    New Alzheimer's drugs are poised to change the market — and in preclinical arenas, researchers are learning more and more about the disease.

    By Dec. 22, 2022
  • Vicki Goodwin Exelexis
    Image attribution tooltip
    Permission granted by Exelexis’ Dr. Vicki Goodman

    Woman of the Week: Exelixis’ Dr. Vicki Goodman

    With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

    By Dec. 14, 2022
  • An illustration of two fingers holding a crystal glass pill with a DNA strip floating inside.
    Image attribution tooltip

    Illustration: Alberto Miranda for Industry Dive


    The 2023 PharmaVoice Year in Preview

    Here’s a look at how industry leaders are navigating the key issues of 2023.

    Dec. 12, 2022
  • A backlit Karuna Therapeutics sign on a teal wall sits behind a white marble reception desk
    Image attribution tooltip
    Permission granted by Karuna Therapeutics

    With FDA filing on the horizon, Karuna appoints new CEO

    Allergan alum Bill Meury will take the helm as current CEO Steve Paul transitions to lead R&D.

    By Dec. 9, 2022
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta

    For Duchenne-focused Sarepta, gene therapy is the natural next step

    The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.

    By Dec. 8, 2022
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen

    10 noteworthy pharma leadership shake-ups this year

    From GSK to Roche to Biogen, these were the most impactful executive changes at leading pharma companies in 2022.

    By Dec. 7, 2022
  • Beatrice McQueen WoW image
    Image attribution tooltip
    Permission granted by Beatrice McQueen

    Woman of the Week: Simcha Therapeutics’ Beatrice McQueen

    From sea sponges to cytokines, the chief operating officer’s career has come full circle as she pursues a new approach to treating cancer via the immune system.

    By Dec. 7, 2022
  • Bill Mezzanotte headshot
    Image attribution tooltip
    Permission granted by CSL

    A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’

    The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug. 

    By Dec. 6, 2022
  • lightbulb breaking
    Image attribution tooltip
    Stock via Getty Images

    Healthcare tech’s biggest busts

    The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.

    By Dec. 2, 2022
  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020, in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    5 final FDA action dates to watch this year

    A potential flurry of regulatory activity could be on the horizon yet this year — and several key drug approvals are at stake.

    By Dec. 1, 2022
  • pills
    Image attribution tooltip
    Stock via Getty Images

    10 of our most popular articles in 2022

    Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

    By Nov. 30, 2022
  • Alison O'Neill B&W head shot
    Image attribution tooltip
    Diego Camargo/PharmaVoice

    Woman of the Week: Surface Oncology’s Dr. Alison O’Neill

    With more than two decades of experience in oncology R&D, Dr. Alison O’Neill is helping Surface unlock the potential of next-gen immunotherapies by targeting the tumor microenvironment.

    By Nov. 30, 2022
  • A team of four people wearing white lab coats stand looking at a computer in a medical science laboratory.
    Image attribution tooltip
    Stock via Getty Images

    One biotech’s approach to science-driven innovation

    Why some in the industry say fostering creativity in drug development is all about work structures.

    By Nov. 29, 2022
  • Skin
    Image attribution tooltip
    Ivan Balvan via Getty Images
    Q&A // Biotech Spotlight

    Evommune’s unique method of drug discovery is more than skin deep

    The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.

    By Nov. 29, 2022
  • Psychedelic
    Image attribution tooltip
    Danylana via Getty Images

    Avoiding a ‘bad trip’ in psychedelic clinical trials

    Psychedelic drug trials pose a number of challenges, but researchers can take these steps to boost patient safety.

    By Kelly Bilodeau • Nov. 28, 2022
  • Nicole Lambert WoW picture
    Image attribution tooltip
    Diego Camargo/PharmaVoice

    Woman of the Week: Myriad Genetics’ Nicole Lambert

    Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.

    By Nov. 23, 2022
  • A view of a sign that reads, "Kendall square: central square, Harvard square, cinema" is framed by a pill outline.
    Image attribution tooltip

    Photo illustration: Shaun Lucas and Karissa Waddick/Industry Dive; Getty Images 

    The next era of Greater Boston’s biotech boom

    How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.  

    By , , Nov. 22, 2022
  • Professional headshot of Evelina Vågesjö
    Image attribution tooltip

    Permission granted by Evelina Vågesjö 


    How bacteria-enabled technology for wounds could also help cancer patients

    Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.

    By Alexandra Pecci • Nov. 22, 2022
  • lab tubes
    Image attribution tooltip
    Stock via Getty Images

    In cancers with very low survival rates, Sellas aims higher

    The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.

    By Kelly Bilodeau • Nov. 21, 2022
  • IPO
    Image attribution tooltip
    AndreyPopov via Getty Images

    Why the biopharma ‘IPO playbook’ changed in 2022

    Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.

    By Nov. 21, 2022
  • Person using a laptop computer on a mixed color background
    Image attribution tooltip


    Sponsored by ClinicalMind

    Can a formal needs assessment simplify Speaker Bureau compliance?

    In the biopharmaceutical industry, phases of innovation and change are often driven by regulatory action.

    Nov. 21, 2022
  • Artificial intelligence in healthcare
    Image attribution tooltip
    ArtemisDiana via Getty Images

    Is AI just hype or a real revolution in pharma? It’s complicated

    Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

    By Nov. 17, 2022
  • Francisco Barriga and Kaloyan Tsanov of the Sloan Kettering Institute
    Image attribution tooltip
    Permission granted by Memorial Sloan Kettering Cancer Center

    To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

    A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.

    By Nov. 16, 2022
  • HLTH conference 2022
    Image attribution tooltip
    Meagan Parrish/PharmaVoice

    #HLTH: ‘Unicorns are real’ — and here’s how they can navigate a challenging biotech market

    Venture capitalists tackle ways companies can stay afloat while the market’s turbulent waters rise.

    By Nov. 15, 2022
  • Professional headshot of Sana Alajmovic.
    Image attribution tooltip

    Permission granted by Sana Alajmovic


    A ‘bold vision’ to prevent diabetes

    Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

    By Alexandra Pecci • Nov. 15, 2022